News

Pharmabiz1d
China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension
China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension: Shanghai, China Tuesday, April 22, 2025, 18:00 Hrs [IST] Ro ...
Le Lézard2d
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Evogene Ltd. a leading computational biology company focused on revolutionizing life-science-based product discovery and ...
Le Lézard2d
4M Therapeutics to Present at the Upcoming American Psychological Association and American Society of Clinical Psychopharmacology Annual Meetings
M Therapeutics Inc. (4MTx), an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative diseases, today announced that the Company's CEO, Pablo Lapuerta, M.D.
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug ...